163 related articles for article (PubMed ID: 3218791)
1. [Activated thromboplastin time, plasma heparin and plasma fibrinogen using the Fibrintimer 10].
Khayat MC; Laforet F; Khayat A; Derlon A; Lequerrec A; Thomas M
Ann Biol Clin (Paris); 1988; 46(8):696-700. PubMed ID: 3218791
[TBL] [Abstract][Full Text] [Related]
2. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between plasma concentration of heparin and biological response determined by 2 APTT reagents of different sensitivities].
Bassini E; Miceli M; Cini S; Francalanci R
Quad Sclavo Diagn; 1986 Jun; 22(2):193-200. PubMed ID: 3823368
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
Lang M; Fey MF; Furlan M; Beck EA
Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
[TBL] [Abstract][Full Text] [Related]
5. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
6. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
7. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
Hürzeler C; von Felten A
Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
[TBL] [Abstract][Full Text] [Related]
8. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
[TBL] [Abstract][Full Text] [Related]
9. [Prothrombin time, activated partial thromboplastin time, plasma fibrinogen determination. Comparison of two automated coagulation systems: Koagulab 40-A and ACL-100].
Barbe D; Bauduer F; Tanguy A
Ann Biol Clin (Paris); 1991; 49(10):507-13. PubMed ID: 1807170
[TBL] [Abstract][Full Text] [Related]
10. Use of the activated partial thromboplastin time for heparin monitoring.
Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
[TBL] [Abstract][Full Text] [Related]
11. Problems by using whole blood in heparin measurements.
Talstad I
Thromb Haemost; 1982 Apr; 47(2):177-81. PubMed ID: 7101239
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Kitchen S; Preston FE
Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the performance of an automatic coagulation tester: the Electra 700].
Cambus JP; Biermé R; Martinou JC; Dousset B
Nouv Rev Fr Hematol (1978); 1985; 27(5):313-20. PubMed ID: 4080541
[TBL] [Abstract][Full Text] [Related]
14. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
15. Lipid class composition and heparin sensitivity in the activated partial thromboplastin time.
Stevenson KJ; Easton AC; Thomson JM; Poller L
Thromb Haemost; 1983 Aug; 50(2):601-3. PubMed ID: 6636037
[TBL] [Abstract][Full Text] [Related]
16. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots.
Dempfle CE; Kälsch T; Elmas E; Suvajac N; Lücke T; Münch E; Borggrefe M
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):765-70. PubMed ID: 19002042
[TBL] [Abstract][Full Text] [Related]
17. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
18. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a bench-top coagulation analyzer for measurement of prothrombin time, activated partial thromboplastin time, and fibrinogen concentrations in healthy dogs.
Mineo HK; Garabed RB
Am J Vet Res; 2007 Dec; 68(12):1342-7. PubMed ID: 18052739
[TBL] [Abstract][Full Text] [Related]
20. Heparin-enhanced inhibitors during reversible disseminated intravascular coagulation.
Marbet GA; Griffith MJ; Roberts HR
Scand J Clin Lab Invest Suppl; 1985; 178():95-8. PubMed ID: 3867125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
